Recruiting at 1 site Phase 4 Psoriasis Vulgaris

Clinical trial for Psoriasis Vulgaris

Official title Psoriatic Immune Response to Tildrakizumab

ClinicalTrials.gov ID: NCT05390515

What this study is testing

What is Tildrakizumab Prefilled Syringe?

An investigational injectable medicine being studied as a potential treatment for moderate to severe plaque psoriasis. It is designed to block interleukin‑23 (IL‑23) signaling, reducing inflammation in the skin.

Also referred to as Ilumya.

Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
This study is looking at how the immune cells in skin and blood work before and after starting tildrakizumab.
Who it's for
You may be able to join if you have psoriasis vulgaris.
What's involved
You will receive tildrakizumab and have skin and blood tests before treatment and later after treatment.
  • Phase 4: studies an already-approved treatment

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 to 75

You may be able to join if

  • 18 years of age or older
  • Patients with moderate-severe psoriasis or \> 5% body surface area affected.

You likely can't join if

  • taking systemic immunosuppressives in the last 4 weeks
  • pregnancy
  • severe immunodeficiency (either from genetic or infectious causes).
  • tuberculosis or other active serious infection
  • active systemic malignancy.
  • breast-feeding
See the full eligibility criteria
Who can join
  • 18 years of age or older
  • Patients with moderate-severe psoriasis or \> 5% body surface area affected.
What rules you out
  • taking systemic immunosuppressives in the last 4 weeks
  • pregnancy
  • severe immunodeficiency (either from genetic or infectious causes).
  • tuberculosis or other active serious infection
  • active systemic malignancy.
  • breast-feeding
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

The study team makes the final eligibility decision.

Where it is enrolling

  • San Francisco, California, United States

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.

Where is this trial taking place?

This study is enrolling now at San Francisco, California, United States. Enter your location above to see the nearest enrolling site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.